| 肌松药拮抗药Sugammadex的临床应用进展 |
| 投稿时间：2012-03-14 修订日期：2012-05-02 点此下载全文 |
| 引用本文：王耘,曹永兵,姜远英,颜天华.肌松药拮抗药Sugammadex的临床应用进展[J].药学实践杂志,2012,30(6):405~407,453 |
| 摘要点击次数: 5951 |
| 全文下载次数: 2662 |
|
|
| 中文摘要:2008年Sugammadex在欧洲获准上市,用于拮抗由罗库溴铵和维库溴铵介导的神经肌肉功能阻滞,显示出较好的有效性和安全性。本文主要关注Sugammadex在常规临床实践中和紧急情况下,对于肌松药物使用所产生的影响,以及Sugammadex在特殊人群患者中的作用效果。 |
| 中文关键词:肌松拮抗 Sugammadex 罗库溴铵 琥珀胆碱 新斯的明 |
| |
| Clinical application of Sugammadex |
|
|
| Abstract:Sugammadex had been licensed for reversal of rocuronium and vecuronium induced neuromuscular blockade in Europe since 2008, which had shown to be efficacious and had a good safety profile so far. The potential for Sugammadex to change the management of NMB, in routine clinical practice, in emergency situations and in special populations were reviewed in this paper. |
| keywords:neuromuscular blockade reversal sugammadex rocuronium suxamethonium neostigmine |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
